143 related articles for article (PubMed ID: 37865134)
21. ROS-Activated homodimeric podophyllotoxin nanomedicine with self-accelerating drug release for efficient cancer eradication.
Liang B; Zhou D
Drug Deliv; 2021 Dec; 28(1):2361-2372. PubMed ID: 34747277
[TBL] [Abstract][Full Text] [Related]
22. A self-assembly nano-prodrug for triple-negative breast cancer combined treatment by ferroptosis therapy and chemotherapy.
Chen Y; Yao Z; Liu P; Hu Q; Huang Y; Ping L; Zhang F; Tang H; Wan T; Ping Y; Li B
Acta Biomater; 2023 Mar; 159():275-288. PubMed ID: 36709836
[TBL] [Abstract][Full Text] [Related]
23. Nanoparticle drug delivery systems responsive to tumor microenvironment: Promising alternatives in the treatment of triple-negative breast cancer.
Cao Y; Meng F; Cai T; Gao L; Lee J; Solomevich SO; Aharodnikau UE; Guo T; Lan M; Liu F; Li Q; Viktor T; Li D; Cai Y
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(2):e1950. PubMed ID: 38528388
[TBL] [Abstract][Full Text] [Related]
24. Redox-Responsive Fluorescent Polycarbonates Based on Selenide for Chemotherapy of Triple-Negative Breast Cancer.
Yu L; Ke HL; Du FS; Li ZC
Biomacromolecules; 2019 Jul; 20(7):2809-2820. PubMed ID: 31185717
[TBL] [Abstract][Full Text] [Related]
25. Combination Organelle Mitochondrial Endoplasmic Reticulum Therapy (COMET) for Multidrug Resistant Breast Cancer.
Milane LS; Dolare S; Ren G; Amiji M
J Control Release; 2023 Nov; 363():435-451. PubMed ID: 37717658
[TBL] [Abstract][Full Text] [Related]
26. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
27. A Self-Assembly Nano-Prodrug for Combination Therapy in Triple-Negative Breast Cancer Stem Cells.
Wu C; Zhang F; Li B; Li Z; Xie X; Huang Y; Yao Z; Chen Y; Ping Y; Pan W
Small; 2023 Oct; 19(41):e2301600. PubMed ID: 37328445
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of cannabinoid receptor type 1 sensitizes triple-negative breast cancer cells to ferroptosis via regulating fatty acid metabolism.
Li P; Lin Q; Sun S; Yang N; Xia Y; Cao S; Zhang W; Li Q; Guo H; Zhu M; Wang Y; Zheng Z; Li S
Cell Death Dis; 2022 Sep; 13(9):808. PubMed ID: 36130940
[TBL] [Abstract][Full Text] [Related]
29. ROS triggered cleavage of thioketal moiety to dissociate prodrug nanoparticles for chemotherapy.
Pan Q; Deng X; Gao W; Chang J; Pu Y; He B
Colloids Surf B Biointerfaces; 2020 Oct; 194():111223. PubMed ID: 32615519
[TBL] [Abstract][Full Text] [Related]
30. Co-targeting Bulk Tumor and CSCs in Clinically Translatable TNBC Patient-Derived Xenografts via Combination Nanotherapy.
Sulaiman A; McGarry S; El-Sahli S; Li L; Chambers J; Phan A; Côté M; Cron GO; Alain T; Le Y; Lee SH; Liu S; Figeys D; Gadde S; Wang L
Mol Cancer Ther; 2019 Oct; 18(10):1755-1764. PubMed ID: 31308079
[TBL] [Abstract][Full Text] [Related]
31. Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells.
Khandelwal S; Boylan M; Spallholz JE; Gollahon L
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373175
[TBL] [Abstract][Full Text] [Related]
32. Transferrin receptor-targeted redox/pH-sensitive podophyllotoxin prodrug micelles for multidrug-resistant breast cancer therapy.
Li Y; Chen M; Yao B; Lu X; Zhang X; He P; Vasilatos SN; Ren X; Bian W; Yao C
J Mater Chem B; 2019 Oct; 7(38):5814-5824. PubMed ID: 31495855
[TBL] [Abstract][Full Text] [Related]
33. Metabolite Profiling Reveals the Glutathione Biosynthetic Pathway as a Therapeutic Target in Triple-Negative Breast Cancer.
Beatty A; Fink LS; Singh T; Strigun A; Peter E; Ferrer CM; Nicolas E; Cai KQ; Moran TP; Reginato MJ; Rennefahrt U; Peterson JR
Mol Cancer Ther; 2018 Jan; 17(1):264-275. PubMed ID: 29021292
[TBL] [Abstract][Full Text] [Related]
34. Probing the impact of sulfur/selenium/carbon linkages on prodrug nanoassemblies for cancer therapy.
Sun B; Luo C; Zhang X; Guo M; Sun M; Yu H; Chen Q; Yang W; Wang M; Zuo S; Chen P; Kan Q; Zhang H; Wang Y; He Z; Sun J
Nat Commun; 2019 Jul; 10(1):3211. PubMed ID: 31324811
[TBL] [Abstract][Full Text] [Related]
35. Anti-Trop2 antibody-conjugated bioreducible nanoparticles for targeted triple negative breast cancer therapy.
Son S; Shin S; Rao NV; Um W; Jeon J; Ko H; Deepagan VG; Kwon S; Lee JY; Park JH
Int J Biol Macromol; 2018 Apr; 110():406-415. PubMed ID: 29055700
[TBL] [Abstract][Full Text] [Related]
36. Ultrasound-guided delivery of thymidine kinase-nitroreductase dual therapeutic genes by PEGylated-PLGA/PIE nanoparticles for enhanced triple negative breast cancer therapy.
Devulapally R; Lee T; Barghava-Shah A; Sekar TV; Foygel K; Bachawal SV; Willmann JK; Paulmurugan R
Nanomedicine (Lond); 2018 May; 13(9):1051-1066. PubMed ID: 29790803
[TBL] [Abstract][Full Text] [Related]
37. ROS-triggered cycle amplification effect: A prodrug activation nanoamplifier for tumor-specific therapy.
Huang Z; Ding Y; Luo Y; Chen M; Zeng Z; Zhang T; Sun Y; Huang Y; Zhao C
Acta Biomater; 2022 Oct; 152():367-379. PubMed ID: 36084924
[TBL] [Abstract][Full Text] [Related]
38. pH-Sensitive Shell-Core Platform Block DNA Repair Pathway To Amplify Irreversible DNA Damage of Triple Negative Breast Cancer.
Dong Y; Liao H; Fu H; Yu J; Guo Q; Wang Q; Duan Y
ACS Appl Mater Interfaces; 2019 Oct; 11(42):38417-38428. PubMed ID: 31556584
[TBL] [Abstract][Full Text] [Related]
39. Olaparib@human serum albumin nanoparticles as sustained drug-releasing tumour-targeting nanomedicine to inhibit growth and metastasis in the mouse model of triple-negative breast cancer.
Vysyaraju NR; Paul M; Ch S; Ghosh B; Biswas S
J Drug Target; 2022 Dec; 30(10):1088-1105. PubMed ID: 35723068
[TBL] [Abstract][Full Text] [Related]
40. CD44-specific nanoparticles for redox-triggered reactive oxygen species production and doxorubicin release.
Lin CW; Lu KY; Wang SY; Sung HW; Mi FL
Acta Biomater; 2016 Apr; 35():280-92. PubMed ID: 26853764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
